These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19149535)

  • 1. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
    Sourris KC; Forbes JM
    Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of AGEs in diabetic nephropathy.
    Fukami K; Yamagishi S; Ueda S; Okuda S
    Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grape seed proanthocyanidins ameliorate diabetic nephropathy via modulation of levels of AGE, RAGE and CTGF.
    Li X; Xiao Y; Gao H; Li B; Xu L; Cheng M; Jiang B; Ma Y
    Nephron Exp Nephrol; 2009; 111(2):e31-41. PubMed ID: 19142024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
    Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
    Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of RAGE for attenuating progression of diabetic vascular complications.
    Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
    Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAGE in diabetic nephropathy.
    Yamamoto H; Watanabe T; Yamamoto Y; Yonekura H; Munesue S; Harashima A; Ooe K; Hossain S; Saito H; Murakami N
    Curr Mol Med; 2007 Dec; 7(8):752-7. PubMed ID: 18331233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
    Zhuang A; Forbes JM
    Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
    Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
    J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAGE: a novel target for drug intervention in diabetic vascular disease.
    Hudson BI; Schmidt AM
    Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of diabetic vascular injury by controlling of AGE-RAGE system.
    Myint KM; Yamamoto Y; Sakurai S; Harashima A; Watanabe T; Li H; Takeuchi A; Yoshimura K; Yonekura H; Yamamoto H
    Curr Drug Targets; 2005 Jun; 6(4):447-52. PubMed ID: 16026264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
    Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
    Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
    Bierhaus A; Ritz E; Nawroth PP
    Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
    Jandeleit-Dahm KA; Lassila M; Allen TJ
    Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products, oxidative stress and diabetic nephropathy.
    Yamagishi S; Matsui T
    Oxid Med Cell Longev; 2010; 3(2):101-8. PubMed ID: 20716934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products (AGEs) and diabetic vascular complications.
    Yamagishi S; Nakamura K; Imaizumi T
    Curr Diabetes Rev; 2005 Feb; 1(1):93-106. PubMed ID: 18220586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AGE-RAGE system and diabetic nephropathy.
    Sakurai S; Yonekura H; Yamamoto Y; Watanabe T; Tanaka N; Li H; Rahman AK; Myint KM; Kim CH; Yamamoto H
    J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S259-63. PubMed ID: 12874443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of advanced glycation end products in diabetic neuropathy.
    Sugimoto K; Yasujima M; Yagihashi S
    Curr Pharm Des; 2008; 14(10):953-61. PubMed ID: 18473845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.